How exercise protects the prostate: a new CNTF pathway that calms tumor‑supporting cells and boosts immune attack

We know that exercise can help reduce the risk of getting prostate cancer and may slow its progression, but exactly how this happens inside the body has remained unclear. A recent study in mice has now uncovered an important new mechanism that links physical exercise to the way tumors behave and how the immune system fights them.

The researchers used a mouse model called TRAMP, which develops prostate tumors similar to human prostate cancer. Mice that followed a long‑term, moderate exercise program showed much slower tumor growth and fewer metastases compared with mice that stayed sedentary. To understand why, the team looked in detail at the tumor microenvironment, the area of tissue that surrounds and interacts with the cancer.

Inside prostate tumors, certain cells called fibroblasts can change into a more aggressive form called myofibroblasts. These myofibroblasts produce a lot of scar‑like tissue and help create an environment that favors tumor growth and blocks immune responses. In the TRAMP mice that did not exercise, this myofibroblast population was high. However, in the exercised mice, the researchers saw that these cells shifted back toward a calmer, more resting state. This change meant less scar tissue and a less supportive environment for the cancer.

The key molecule that connected exercise to these changes was a cytokine called ciliary neurotrophic factor, or CNTF. Exercise increased the levels of CNTF in the body, and this molecule acted on the fibroblasts in the prostate tumor area. CNTF helped prevent or reverse the transition into myofibroblasts, effectively calming down the reactive stroma around the tumor. At the same time, regions with higher CNTF showed more infiltration of CD8⁺ T cells, a type of immune cell that can recognize and kill cancer cells. This suggests that CNTF helps switch the tumor microenvironment from a shielded, immunosuppressive state into one where the immune system can better attack the cancer.

To test whether CNTF itself could be used as a treatment, the scientists gave mice recombinant CNTF, a lab‑made version of the protein. They found that this treatment slowed tumor growth even in mice that did not exercise. More importantly, when CNTF was combined with immune checkpoint blockade drugs, which aim to “release the brakes” on the immune system, the anti‑tumor effect was stronger than either treatment alone. This points to CNTF as a potential way to make prostate tumors more responsive to immunotherapy.

Although these findings are still in mice, they provide a strong rationale for studying CNTF‑based approaches and exercise programs in people with prostate cancer, with the goal of improving survival and response to treatments.

Source.